Home » Stocks » Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. (RETA)

Stock Price: $149.27 USD -0.02 (-0.01%)
Updated Aug 4, 2020 3:40 PM EDT - Market open

Stock Price Chart

Key Info

Market Cap 4.26B
Revenue (ttm) 20.10M
Net Income (ttm) -309.96M
Shares Out 28.51M
EPS (ttm) -9.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $149.27
Previous Close $149.29
Change ($) -0.02
Change (%) -0.01%
Day's Open 151.45
Day's Range 147.12 - 153.40
Day's Volume 191,558
52-Week Range 70.00 - 257.97

More Stats

Market Cap 4.26B
Enterprise Value 3.79B
Earnings Date (est) Aug 10, 2020
Ex-Dividend Date n/a
Shares Outstanding 28.51M
Float 25.76M
EPS (basic) -10.03
EPS (diluted) -9.92
FCF / Share -7.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.55M
Short Ratio 8.39
Short % of Float 16.94%
Beta 2.03
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 211.71
PB Ratio 22.56
Revenue 20.10M
Operating Income -324.03M
Net Income -309.96M
Free Cash Flow -265.19M
Net Cash 468.98M
Net Cash / Share 16.45
Gross Margin -1,124.33%
Operating Margin -1,612.11%
Profit Margin -1,542.10%
FCF Margin -1,319.35%
ROA -40.69%
ROE -276.70%
ROIC -4,028.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 7
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$281.12*
(88.33% upside)
Low
237
Current: $149.27
High
345
Target: 281.12
*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue26.5253.5948.0649.8650.3251.95
Revenue Growth-50.52%11.51%-3.61%-0.92%-3.15%-
Gross Profit26.5253.5948.0649.8650.3251.95
Operating Income-285-76.88-46.91-6.88-0.333.63
Net Income-290-80.55-47.67-6.23-1.450.69
Shares Outstanding30.4127.7023.9319.8215.9715.95
Earnings Per Share-9.54-2.91-1.99-0.31-0.090.04
Operating Cash Flow-251-83.78-83.26-19.26-44.62-88.63
Capital Expenditures-2.67-0.68-0.34-0.34-0.26-0.14
Free Cash Flow-254-84.46-83.60-19.60-44.88-88.77
Cash & Equivalents66433813084.7373.930.00
Total Debt15579.2219.61---
Net Cash / Debt50925911084.7373.930.00
Assets68234513589.0978.95-
Liabilities426330282304352-
Book Value25715.16-147-215-273-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Reata Pharmaceuticals, Inc.
Country United States
Employees 220
CEO J. Warren Huff

Stock Information

Ticker Symbol RETA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: RETA
IPO Date May 26, 2016

Description

Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.